Catherine R Weiler, K Frank Austen, Cem Akin, Marla S Barkoff, Jonathan A Bernstein, Patrizia Bonadonna, Joseph H Butterfield, Melody Carter, Charity C Fox, Anne Maitland, Thanai Pongdee, S Shahzad Mustafa, Anupama Ravi, Mary C Tobin, Harissios Vliagoftis, Lawrence B Schwartz
Our current recommendations for diagnosing and treating primary mast cell (MC) activation syndrome make use of the latest studies and consensus guidelines for clinically recognizing systemic anaphylaxis in real time, regardless of whether allergen-triggered or other pathways are involved; our current understanding of the biomarkers secreted by activated MCs that best discriminate this disorder from other conditions; and the therapeutic drugs that might selectively affect those mediators or MCs themselves. Finding familial or somatic mutations of genes that cause MCs to be hyperactivatable would extend our diagnostic tools and potentially indicate new therapeutic interventions, targeting either the mutated gene product or the associated molecular pathway...
October 2019: Journal of Allergy and Clinical Immunology